Single-Pulse Transcranial Magnetic Stimulation (sTMS) Technology: eNeura's SAVI Dual Device and Its Role in the Migraine Market.

Clicks: 52
ID: 283179
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 2 articles by views in ieee pulse

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Migraine, a debilitating neurological disorder affecting over 1 billion people worldwide, has long challenged medical science due to its complex pathophysiology and variable treatment responses. Single-pulse transcranial magnetic stimulation (sTMS), a noninvasive central neuromodulation technique, has emerged as a promising therapeutic option. Developed by eNeura Inc., the SAVI Dual device leverages sTMS to provide both acute and preventive migraine relief by targeting hyperactive neural networks in the brain. This article explores the technical underpinnings of SAVI Dual, traces the history of clinical studies that shaped sTMS for neuromodulation, and evaluates its position within the evolving migraine market.
Reference Key
bohlen2025singlepulse Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bohlen, Eric
Journal ieee pulse
Year 2025
DOI
10.1109/MPULS.2025.3554830
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.